Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Phase 2 Interventional Results available

NSAID Effects on Clinical and Imaging Breast Biomarkers

NCT01761877
View directory record Official record
Conditions
Inflammation, Cancer, Pain, Hypertension
Interventions
Sulindac
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Up to 75 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Tucson, Arizona • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257
View directory record Official record
Conditions
Tinea Pedis
Interventions
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream, UHE-103A1B cream, UHE-103A2B cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
San Diego, California • Melbourne, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

NCT04128579
View directory record Official record
Conditions
Lupus Erythematosus, Lupus Nephritis
Interventions
Itolizumab [Bmab 600]
Drug
Lead sponsor
Biocon Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
MGTA-456
Drug
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients

NCT01876329
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 30, 2026, 2:24 PM EDT
Terminated Early Phase 1 Interventional

Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer

NCT01138553
View directory record Official record
Conditions
Invasive Breast Cancer, Ductal Carcinoma in Situ
Interventions
Mifepristone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05727839
View directory record Official record
Conditions
Cutaneous Tumor, Malignant Solid Tumor
Interventions
JCXH-211 Injection
Drug
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Integrated Intervention for Breast Cancer Survivors With Diabetes

NCT05092477
View directory record Official record
Conditions
Diabetes, Breast Cancer
Interventions
Integrated Intervention for Breast Cancer Survivors with Diabetes, Attention Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational

Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors

NCT00872677
View directory record Official record
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
Diet, Spiritual counseling
Behavioral · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557
View directory record Official record
Conditions
Melanoma, Herpetic Infection
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

NCT00428922
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Bevacizumab, Docetaxel
Drug
Lead sponsor
Bhuvaneswari Ramaswamy
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma

NCT01859845
View directory record Official record
Conditions
Melanoma
Interventions
Smartphone
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

NCT00430495
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Durapore vs. Hy-Tape to Secure The Endotracheal Tube

NCT03633877
View directory record Official record
Conditions
Erythema
Interventions
DuraporeTM and Hy-Tape®
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 30, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Oral Warts in HIV+ Patients

NCT00454181
View directory record Official record
Conditions
Papillomatosis, HIV Infections
Interventions
Interferon-alpha, placebo
Drug · Other
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 30, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional Results available

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

NCT02129205
View directory record Official record
Conditions
Neoplasms, Breast Cancer
Interventions
PF-06650808
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 30, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation

NCT03143894
View directory record Official record
Conditions
Breast Cancer, Cognitive Dysfunction, Fatigue
Interventions
tDCS, Sham tDCS
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 30, 2026, 2:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 2:24 PM EDT
Terminated Not applicable Interventional

Improving Communication With Patients With Breast Cancer

NCT00276822
View directory record Official record
Conditions
Breast Cancer
Interventions
communication intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 30, 2026, 2:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

NCT03775031
View directory record Official record
Conditions
Skin Cancer
Interventions
Fractional Laser and Chemical Peel
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation

NCT01386775
View directory record Official record
Conditions
Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
1 Year and older · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
O'Fallon, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 30, 2026, 2:24 PM EDT
Completed No phase listed Observational

Longitudinal Studies of Brain Structure and Function in MPS Disorders

NCT01870375
View directory record Official record
Conditions
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis Type IV, Mucopolysaccharidosis Type VII
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
3
States / cities
Oakland, California • Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 30, 2026, 2:24 PM EDT